Alcon Expands Its Cell Therapy Ambitions With $550M Neurotech Pharma Acquisition
Alcon’s Neurotech Pharmaceuticals acquisition brings the rare vision disorder cell therapy Encelto as well as the platform technology that developed it. Last year, Alcon acquired a...
NervGen Reports Third Quarter 2026 Financial Results and Provides Business Updates
MIAMI, Nov. 16, 2026 (GLOBE NEWSWIRE) — NervGen (NASDAQ: NGEN), a late-stage clinical biopharmaceutical company developing first-in-class neuroreparative…
Optogenics researchers win a Nobel Prize; Roche bets on Alector brain drug
The Nobel laureates “laid the foundation” for a new field of brain research, the award committee wrote. Elsewhere, Roche and CSL cut licensing deals and the FDA endorsed broader us...
Rapport’s epilepsy drug finds surprising success in bipolar trial
Despite what some analysts described as low expectations, RAP-219 narrowly hit the main goal of a mid-stage study, results that could help it tap a billion-dollar-plus market oppor...
Takeda debuts narcolepsy drug targeting root cause, capping 15-year effort
Axonics
Axonics Anonymous (not verified) Mon, 11/16/2026 - 00:40 field_thread_url https://cafepharma.com/boards/threads/axonics.704805/ board na...
DataMEDS AI Enters Into Agreement for Commercial Supply of Six Peptides Recommended by FDA Advisory Committee
Corexa Pharmacy to dispense compounded BPC-157, TB-500, KPV, MOTS-c, Epitalon and Semax in accordance with HHS' recently updated Enforcement Discretion PolicyBulk drug substance ac...
A New Neurotech Startup Launches to Rival Sam Altman’s Merge Labs
Bridge Neurotech is planning to build a wearable brain-computer interface that uses ultrasound.
Pasithea Therapeutics Reports Positive Early Trial Results for PAS-004 in Neurofibromatosis
MIAMI, Nov. 13, 2026 (GLOBE NEWSWIRE) — Pasithea Therapeutics Corp. (Nasdaq: KTTA) (“Pasithea” or the “Company”), a clinical-stage…
A Takeda spinout builds case for its Parkinson’s drug
Cerevance plans to meet with the FDA to “determine next steps” for a new kind of medicine known as solengepras, now that it has Phase 3 data in hand.
SpyGlass Pharma reports 4-year glaucoma implant trial results
NexTel Medical Corp. Announces Next-Generation Wellness Product Line Incorporating FDA-Approved Pharmaceuticals
Innovative Delivery Technologies Aimed at Enhancing Bioavailability and Expanding Patient Access Beyond Traditional Injections
Neuvivo appoints Michael McGrath MD, PhD as Chief Executive Officer
Appointment follows 12-month interim tenure of scientific, regulatory and commercial achievements for Phase 3 trial preparation in ALS PALO ALTO, Calif., Nov. 13, 2026 /PRNewswire-...
London biotech Oyster harvests $60M for tau-targeting brain drugs
Oyster says a tweak it's made to traditional protein degrading technology can help break down tau, which has long been a focus of Alzheimer’s drug research.
Parkinson’s cell therapy developer files to go public
Aspen Neuroscience is looking to join the Nasdaq and raise more money to support its lead program, which aims to turn a patient's own cells into dopamine-producing neurons.
Consano Bio Raises More Than $15 Million in Oversubscribed Financing to Advance C-1101 in Chronic Painful Lumbosacral Ra...
Proceeds will fund completion of the Phase 1 trial and continued development of C-1101, a potential first-in-class disease-modifying therapeutic -- Clinical data expected in 1H 202...
Ensysce Biosciences Phase 2 Protocol for CY200 - A Neuroplastigen for the Treatment of CRPS - Submitted to the UK MHRA
~ Submission to the UK MHRA for review marks critical step towards initiating a Phase 2 Study with CY200 ~
This week in charts: Brain drugs are back on venture capitalists’ minds
Five neurology-focused startups have together raised around $450 million in the last few weeks. Elsewhere, investors had a muted response to the latest cell therapy research.
Priovant
Priovant Anonymous (not verified) Fri, 11/06/2026 - 18:33 field_thread_url https://cafepharma.com/boards/threads/priovant.718186/ board...
<![CDATA[Roundup: Teva Acquires BXCL501 for $57.5 Million Upfront, Rumi Therapeutics Enters Option Agreement for Frag...
NervGen Receives FDA Breakthrough Therapy Designation for NVG-291 in Chronic Spinal Cord Injury
Breakthrough Therapy designation granted based on FDA’s review of safety and efficacy data from the chronic cohort of the Phase 1b/2a CONNECT SCI study.
Turn fresh research into a full content calendar
Use SocialBu to discover ideas, generate post drafts, and schedule them across your social channels.